Belgian Brothers Grow Sought-After Mushrooms for Brain Health
In a small, climate-controlled facility in the Netherlands, David and Dries, aged 25 and 27 respectively, are cultivating a specialized variety of mushroom believed to offer cognitive benefits. The pair, who have not disclosed their last names, are responding to growing interest in psilocybin mushrooms and their potential impact on brain health, though the legal status of such cultivation remains complex.
The mushrooms, a species not yet widely identified in public reports, are being grown with a focus on maximizing psilocybin content, a naturally occurring psychedelic compound. While research into psilocybin’s therapeutic applications is expanding, particularly in the treatment of depression and anxiety, its recreational use remains illegal in many jurisdictions. The Netherlands maintains a unique legal framework where psilocybin mushrooms are technically illegal, but “magic truffles” – the sclerotia of the fungus – are permitted for sale.
The venture by David and Dries comes as scientific investigation into the neurological effects of psilocybin intensifies. Studies suggest the compound may promote neuroplasticity, the brain’s ability to form new connections, potentially aiding in recovery from neurological conditions and enhancing cognitive function. However, experts caution that self-medication with psilocybin carries risks, including anxiety, paranoia and potential interactions with existing medications.
David C. Dries, MD, a pediatric ophthalmologist at the University of Utah Health, has conducted research on the genetic basis of eye diseases in children, retinopathy of prematurity and amblyopia. While this work is unrelated to the mushroom cultivation in the Netherlands, it highlights the growing scientific interest in understanding the biological mechanisms underlying brain function and neurological disorders. Dr. Dries’s research, as detailed on the University of Utah Health website, focuses on the complexities of the human brain and its potential for healing and adaptation.
Separately, David J. Dries, MD, MSE, a Distinguished Scholar at HealthPartners, chairs the Trauma Surgery department at the University of Minnesota. His research focuses on critical care, trauma, and mass casualty care modeling, including studies on outcomes after traumatic injury and the impact of geriatric status on recovery. Recent publications from his team at HealthPartners, including a 2026 study on outcomes after splenic injury in geriatric trauma, demonstrate a continued focus on understanding and improving patient care in high-stress medical situations.
The cultivation operation in the Netherlands is currently operating on a small scale, with David and Dries focusing on perfecting their growing techniques and ensuring product quality. They have not yet announced plans for commercial distribution, citing the necessitate for further research and clarity regarding the legal landscape surrounding psilocybin-containing products. The pair have not responded to requests for comment regarding their long-term goals or potential partnerships.
The HealthPartners research team led by David J. Dries, MD, MSE, is also investigating radiation injury, suggesting a broad interest in understanding the body’s response to trauma and exploring potential therapeutic interventions. Their ongoing work on mass casualty care modeling could have implications for disaster preparedness and the development of effective treatment protocols in emergency situations.